Printer Friendly

CHUGAI-RHONE-POULENC OBTAINS POSITIVE EUROPEAN RECOMMENDATION FOR GRANOCYTE(R) (lenograstim:rHuG-CSF)

 COLLEGEVILLE, Pa., June 30 /PRNewswire/ -- Chugai-Rhone-Poulenc, a joint venture between Chugai Pharmaceutical Company and Rhone-Poulenc Rorer (NYSE: RPR), announced today that the Committee for Proprietary Medicinal Products (CPMP) has granted a positive recommendation on the use of Granocyte(R) (lenograstim:rHuG-CSF).
 The announcement was made at the 18th International Congress of Chemotherapy in Stockholm, Sweden.
 Dr. Joanna Horobin, General Manager, Chugai-Rhone-Poulenc, said, "It was only three years ago that the joint venture was established with the objective of introducing the first Japanese pharmaceutical biotech product in Europe. Today we are announcing that the European CPMP has made a positive recommendation for the marketing authorization for Granocyte(R)."
 Developed by Chugai-Rhone-Poulenc, lenograstim is the only human- identical glycosylated rHuG-CSF (recombinant human granulocyte colony stimulating factor) which has been granted a positive opinion for use in reducing the duration of severe neutropenia and associated complications in cancer patients undergoing toxic chemotherapy and bone marrow transplantation. Neutropenia, a frequent side-effect of many cancer treatments, is a reduction in the number of white blood cells called neutrophils. Neutropenia impairs the patient's defense against infection, and often delays and limits the chemotherapy which can be administered.
 Granocyte(R) was developed and launched successfully by the Chugai Pharmaceutical Company in Japan in December, 1991 as Neutrogin(R), generating first-year sales of $155 million dollars (IMS). In Europe, Granocyte(R) will be marketed by Rhone-Poulenc Rorer. In the UK, it will be marketed jointly with Chugai.
 Chugai-Rhone-Poulenc is a joint venture company formed in 1990 between the Chugai Pharmaceutical Company Ltd. in Tokyo (55 percent equity holding) and Rhone-Poulenc Rorer (45 percent equity holding). Chugai-Rhone-Poulenc is dedicated to the development of the granulocyte colony stimulating factor, Granocyte(R) (lenograstim:rHuG-CSF) for the European market.
 Chugai Pharmaceutical Company Ltd., the first company in the world to develop human-identical glycosylated G-CSF, is one of Japan's most forward-looking companies. The company reported sales of $1.2 billion and invested 15percent of their sales in research and development in 1992.
 Rhone-Poulenc Rorer is a global pharmaceutical company dedicated to the discovery, development, manufacture and marketing of human pharmaceuticals. The company reported sales of $4.1 billion and invested over $500 million in research and development in 1992.
 /delval/
 -0- 6/30/93
 /CONTACT: Sue Mulholland (investor), 215-454-3852, or Bob Pearson (media), 215-454-3872/
 (RPR)


CO: Chugai-Rhone-Poulenc; Chugai Pharmaceutical Company;
 Rhone-Poulenc Rorer ST: Pennsylvania IN: MTC SU:


MK -- PH012 -- 7102 06/30/93 11:08 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 30, 1993
Words:403
Previous Article:INNOVATIVE NEW PROGRAM LAUNCHES ON PAY-PER-VIEW IN THE FALL; SASSON SPONSORS 90-MINUTE GUIDE TO THE PSAT, SAT AND COLLEGE ADMISSIONS
Next Article:KATY INDUSTRIES, INC. COMMON STOCK DIVIDEND DECLARED
Topics:


Related Articles
LARGE STUDY SHOWS NEW G-CSF LEADS TO FEWER DAYS OF INFECTION, LESS USE OF ANTIBIOTICS AND EARLIER HOSPITAL DISCHARGE
TAXOTERE(R) (docetaxel) RECEIVES APPROVAL IN 15 COUNTRIES OF EUROPEAN UNION (EU) FOR TREATMENT OF ADVANCED BREAST CANCER
MORE POTENT DRUG AVAILABLE FOR BLOOD STEM CELL MOBILIZATION
RHONE-POULENC RORER OBTAINS EXTENDED RIGHTS TO MARKET CAMPTO(R), A NEW ANTICANCER AGENT
INVESTIGATORS SAY GRANOCYTE(R) (LENOGRASTIM) SPEEDS RECOVERY OF NEUTROPHILS, CUTTING HOSPITAL STAYS, COSTS AFTER BLOOD STEM CELL REINFUSION
NEW ANTICANCER AGENT, TAXOTERE, CLEARED FOR USE IN NINE ADDITIONAL COUNTRIES
New Anticancer Agent Taxotere(R) Cleared for Use in Japan; First Taxoid to be Approved in Country
ESMO/Rhone-Poulenc Rorer Fellowship Awarded To Adam Pawinski, M.D.
New Indication for Granocyte(R) Will Enable European Cancer Patients To Avoid Bone Marrow Transplantation
Rhone-Poulenc Rorer Obtains Exclusive Rights to Market Granocyte(R) (Lenograstim) in 39 Additional Countries

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters